Literature DB >> 19688333

Toll-like receptors in multiple sclerosis.

Michael K Racke1, Paul D Drew.   

Abstract

Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) characterized by inflammation, demyelination, and axonal pathology. The exact causes of MS are unknown, but environmental factors including pathogens are believed to contribute to the development of disease. Toll-like receptors (TLRs) are a family of receptors important in pathogen recognition and host defense. TLRs are expressed by a variety of peripheral immune cells as well as resident cells of the CNS. Studies indicate that TLRs play a significant role in modulating MS, as well as experimental autoimmune encephalomyelitis (EAE), an animal model of MS. This review will discuss the current understanding of the role of TLRs in modulating EAE and MS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19688333      PMCID: PMC3064511          DOI: 10.1007/978-3-642-00549-7_9

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  91 in total

1.  Cutting Edge: TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-beta.

Authors:  Tarik Touil; Denise Fitzgerald; Guang-Xian Zhang; Abdolmohamad Rostami; Bruno Gran
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

Review 2.  Expression and function of Toll-like receptors in T lymphocytes.

Authors:  Dieter Kabelitz
Journal:  Curr Opin Immunol       Date:  2006-11-28       Impact factor: 7.486

3.  CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE.

Authors:  Samantha L Bailey; Bettina Schreiner; Eileen J McMahon; Stephen D Miller
Journal:  Nat Immunol       Date:  2007-01-07       Impact factor: 25.606

Review 4.  Role of B cells in pathogenesis of multiple sclerosis.

Authors:  Behrouz Nikbin; Mandana Mohyeddin Bonab; Farideh Khosravi; Fatemeh Talebian
Journal:  Int Rev Neurobiol       Date:  2007       Impact factor: 3.230

Review 5.  Janus faces of microglia in multiple sclerosis.

Authors:  Patricia Sanders; Jacques De Keyser
Journal:  Brain Res Rev       Date:  2007-03-12

6.  Peroxisome proliferator-activated receptor-gamma agonists suppress the production of IL-12 family cytokines by activated glia.

Authors:  Jihong Xu; Paul D Drew
Journal:  J Immunol       Date:  2007-02-01       Impact factor: 5.422

Review 7.  Multiple sclerosis: a complicated picture of autoimmunity.

Authors:  Henry F McFarland; Roland Martin
Journal:  Nat Immunol       Date:  2007-09       Impact factor: 25.606

Review 8.  Systemic infections in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Simone C Tauber; Roland Nau; Joachim Gerber
Journal:  Arch Physiol Biochem       Date:  2007-06       Impact factor: 4.076

Review 9.  The CD8 T cell in multiple sclerosis: suppressor cell or mediator of neuropathology?

Authors:  Aaron J Johnson; Georgette L Suidan; Jeremiah McDole; Istvan Pirko
Journal:  Int Rev Neurobiol       Date:  2007       Impact factor: 3.230

10.  Synergistic interaction between Toll-like receptor agonists is required for induction of experimental autoimmune encephalomyelitis in Lewis rats.

Authors:  Norbert A Wolf; Taba K Amouzegar; Robert H Swanborg
Journal:  J Neuroimmunol       Date:  2007-03-06       Impact factor: 3.478

View more
  15 in total

Review 1.  Immune modulating peptides for the treatment and suppression of multiple sclerosis.

Authors:  Ahmed H Badawi; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2012-06-05       Impact factor: 3.969

2.  Ghrelin inhibits high glucose-induced PC12 cell apoptosis by regulating TLR4/NF-κB pathway.

Authors:  Xiaoyan Liu; Qian Xiao; Kexiang Zhao; Yuan Gao
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

3.  Identification of TLR2 as a Key Target in Neuroinflammation in Vascular Dementia.

Authors:  Yuye Wang; Shuang Lv; Xiao Zhou; Xiaoqian Niu; Leian Chen; Ziyuan Yang; Dantao Peng
Journal:  Front Genet       Date:  2022-07-06       Impact factor: 4.772

4.  Viral-toxin interactions and Parkinson's disease: poly I:C priming enhanced the neurodegenerative effects of paraquat.

Authors:  Jessica Bobyn; Emily N Mangano; Anusha Gandhi; Eric Nelson; Kerry Moloney; Melanie Clarke; Shawn Hayley
Journal:  J Neuroinflammation       Date:  2012-05-04       Impact factor: 8.322

Review 5.  Does helminth activation of toll-like receptors modulate immune response in multiple sclerosis patients?

Authors:  Jorge Correale; Mauricio F Farez
Journal:  Front Cell Infect Microbiol       Date:  2012-08-24       Impact factor: 5.293

6.  Wogonin improves histological and functional outcomes, and reduces activation of TLR4/NF-κB signaling after experimental traumatic brain injury.

Authors:  Chien-Cheng Chen; Tai-Ho Hung; Yen-Ho Wang; Chii-Wann Lin; Pei-Yi Wang; Chun-Yen Lee; Szu-Fu Chen
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

7.  β-Lapachone ameliorization of experimental autoimmune encephalomyelitis.

Authors:  Jihong Xu; Gail Wagoner; James C Douglas; Paul D Drew
Journal:  J Neuroimmunol       Date:  2012-09-23       Impact factor: 3.221

8.  Selective serotonin reuptake inhibitor attenuates the hyperresponsiveness of TLR2+ and TLR4+ Th17/Tc17-like cells in multiple sclerosis patients with major depression.

Authors:  Marisa C Sales; Taissa M Kasahara; Priscila M Sacramento; Átila D Rossi; Marcos Octávio S D Cafasso; Hugo A A Oyamada; Joana Hygino; Fabianna Alvim; Regis M Andrade; Cláudia Cristina Vasconcelos; Cleonice A M Bento
Journal:  Immunology       Date:  2020-11-23       Impact factor: 7.397

9.  Impaired toll-like receptor 8 signaling in multiple sclerosis.

Authors:  Tory P Johnson; Richa Tyagi; Karan Patel; Nicoline Schiess; Peter A Calabresi; Avindra Nath
Journal:  J Neuroinflammation       Date:  2013-06-21       Impact factor: 8.322

Review 10.  Suppression of TLR signaling by targeting TIR domain-containing proteins.

Authors:  Ota Fekonja; Monika Avbelj; Roman Jerala
Journal:  Curr Protein Pept Sci       Date:  2012-12       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.